Gilead Sciences, Inc. $GILD Shares Sold by Holocene Advisors LP

Key Points

• Holocene Advisors LP cut its Gilead stake by 51.8% in Q3, selling 2,809,799 shares and now owning 2,617,172 shares worth about $290.5 million.
• Insiders have sold a total of 303,280 shares in the past 90 days (≈$43.2M), including disclosed sales by Jeffrey Bluestone and Johanna Mercier, leaving insiders with 0.27% ownership.
• Gilead beat quarterly estimates with $1.86 EPS and $7.93B revenue, issued FY2026 guidance of $8.45–$8.85 EPS, and raised the quarterly dividend to $0.82 (annualized $3.28, ~2.3% yield).

Holocene Advisors LP lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 51.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,617,172 shares of the biopharmaceutical company's stock after selling 2,809,799 shares during the quarter. Holocene Advisors LP owned 0.21% of Gilead Sciences worth $290,506,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in GILD. Csenge Advisory Group boosted its stake in shares of Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock worth $2,375,000 after acquiring an additional 16,288 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock worth $8,713,000 after purchasing an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. grew its holdings in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock valued at $1,115,000 after purchasing an additional 7,168 shares during the last quarter. Railway Pension Investments Ltd increased its position in shares of Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth $1,274,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director owned 8,920 shares of the company's stock, valued at $1,101,620. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares of the company's stock, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 303,280 shares of company stock valued at $43,203,470. Insiders own 0.27% of the company's stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst optimism — Jefferies and other firms have initiated or reiterated positive coverage, highlighting Gilead’s strong HIV franchise, expanding oncology/cell therapy pipeline and long IP runway (through ~2036), which supports both income and growth narratives. How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story
• Positive Sentiment: Zacks raised near-term EPS estimates (Q1/Q2 and FY2027 upgrades reported), nudging earnings expectations higher — a constructive signal for investors focused on fundamentals. The Zacks Analyst Blog: Oracle, T‑Mobile, Gilead and C&F Financial
• Positive Sentiment: Unusually large call-option activity (130k+ calls) signals bullish positioning by traders, which can amplify upside if catalysts continue. (Market data)
• Positive Sentiment: Index and institutional flows — rising institutional focus amid Nasdaq‑100 dynamics can support demand for GILD shares from passive and quant funds. Gilead NASDAQ: GILD Institutional Focus Rises In Nasdaq 100 Index
• Neutral Sentiment: Acquisition rationale — coverage and analyst pieces discuss whether the ~$7.8B Arcellx buy strengthens Gilead’s cell‑therapy franchise amid declining cell therapy sales; the strategic case is positive but clinical/commercial risks remain. Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
• Neutral Sentiment: Market context — broader investor flows into growth/tech vs. traditional defensives are affecting healthcare sector moves; this macro backdrop is neither uniquely positive nor negative for Gilead. Why Investors Aren’t Fleeing to Safe‑Haven Stocks
• Negative Sentiment: Deal/legal risk — a law firm (Kahn Swick & Foti) is investigating Arcellx’s proposed sale to Gilead, citing concerns over price/process; shareholder litigation or regulatory scrutiny could delay or alter the transaction terms and is a near‑term overhang. Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $144.99 on Monday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The stock has a market capitalization of $179.99 billion, a P/E ratio of 21.42, a P/E/G ratio of 1.90 and a beta of 0.36. The firm's 50-day moving average is $140.62 and its two-hundred day moving average is $126.96. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company's revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences's payout ratio is presently 48.45%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GILD. Rothschild & Co Redburn raised their target price on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. Daiwa Securities Group upped their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. UBS Group raised their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Cantor Fitzgerald lifted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 11th. Finally, Mizuho upped their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an "outperform" rating in a research note on Wednesday, February 18th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.